Advanced Merkel cell carcinoma - Pipeline Insight, 2024

This “Advanced Merkel cell carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Merkel cell carcinoma Understanding

Advanced Merkel cell carcinoma: Overview

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors.

Advanced Merkel cell carcinoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Merkel cell carcinoma pipeline landscape is provided which includes the disease overview and Advanced Merkel cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Merkel cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Merkel cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Merkel cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Merkel cell carcinoma.

Advanced Merkel cell carcinoma Emerging Drugs Chapters

This segment of the Advanced Merkel cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Merkel cell carcinoma Emerging Drugs

Tidutamab: Xencor, Inc.Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.

Cabozantinib: ExelixisIn the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Merkel cell carcinoma.

Advanced Merkel cell carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Merkel cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Merkel cell carcinoma

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced Merkel cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Merkel cell carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Merkel cell carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Merkel cell carcinoma drugs.

Advanced Merkel cell carcinoma Report Insights

• Advanced Merkel cell carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Merkel cell carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Merkel cell carcinoma drugs?
• How many Advanced Merkel cell carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Merkel cell carcinoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Merkel cell carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Merkel cell carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• 4SC AG
• Xencor, Inc.
• Incyte Corporation
• Millennium Pharmaceuticals, Inc.
• Exelixis
• Bristol-Myers Squibb
• bluebird bio
• Affini-T Therapeutics
• ImaginAb, Inc.
• BioInvent International AB
• Ocellaris Pharma, Inc.
• Sotio a.s.
• Morphogenesis, Inc.
• Checkpoint Therapeutics, Inc.

Key Products

• Tidutamab
• Domatinostat
• MLN0128
• Cabozantinib
• Nivolumab
• FH-MCVA2TCR
• SO-C101
• CK-301
• IFx-Hu2.0
• 89Zr-Df-Crefmirlimab
• BT-001
• OC-001

This product will be delivered within 1-3 business days.